

Substitute for Form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)

considered. Include copy of this form with next communication to applicant.

ATTY DOCKET NO. 6750-174-999	APPLICATION NO.		
(CAM No. 305158-999172)	10/625,70	8	
APPLICANT:	•		
Donald J. KYLE et al.			
FILING DATE:	ART UNIT:	CONF. NO.:	
July 24, 2003	1624	8122	

			U.S. PAT	ENT DOCUMENTS	
EXAMINER'S INITIALS*	Cite No.	DOCUMENT NUMBER	DATE MM/DD/YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
KN	A27	2004/0259931 A1	12/23/2004	Goodfellow et al.	
	A28				

	FOREIGN PATENT DOCUMENTS						
EXAMINER'S INITIALS*	Cite No.	Country Code, Number, Kind of Code (if known)	DATE MM/DD/YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	TRANSL N	ATIO
I.VIII.		\				YES	NO
KN	B14	WO 00/39117	07/06/2000	Eli Lilly and Company			
KY	B15	JP 2003192673	07/09/2003	Bayer AG		xxx	
	B16						<u> </u>

		NON PATENT LITERATURE DOCUMENTS
EXAMINER'S INITIALS*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, etc.,), date, page(s)s, volume, publisher, city and/or country where published., etc.
KN	C32	SOLYOM et al., "Thiokarbamidderivate mit tuberkulostatischer wirkung, I Verbindungen mit heterocyklischem thiokarbamidskelett," Acta Chimical Academiae Scientarum Hungaricae, Tomus 68(1-2):99-132 (1971)
	C33	SOLYOM et al., "Thiocarbamide derivatives with tuberculostatic action, I Compounds with heterocyclic thiocarbamide skeleton," Acta Chimical Academiae Scientarum Hungaricae, Tomus 68(1-2):99-132 (1971); English translation of C32 obtained from National Translations Center
	C34	WRIGGLESWORTH et al., "Capsaicin-like Agonists," Drugs of the Future 23(5):531-538 (1998)
	C35	SZALLASI et al., "Vanilloid (Capsaicin) Receptors and Mechanisma," Pharmacol. Revs. 51(2):159-211 (1999)
1	C36	SZALLASI et al., "The Cloned Rat Vanilloid Receptor VR1 Mediates Both R-Type Binding and C-Type Calcium Response in Dorsal Root Ganglion Neurons," Molec. Pharmacol. 56:581-587 (1999)
	C37	BEVAN et al., "Vanilloid Receptors: Pivotal Molecules in Nocciception," Current Opinions in CPNS Investigational Drugs, 2(2):178-185 (2000)
	C38	WANG et al., "High Affinity Antagonists of the Vanilloid Receptor," Mol. Pharmacol. 62(4):947-956 (2002)
	C39	LOPEZ-RODRIQUEZ et al., "VR1 Receptor Modulators as Potential Drugs for Neuropathic Pain," Mini-Revs in Medicinal Chem. 3(7):729-748 (2003)
	C40	POMONIS et al., "N-(4-Tertiarybutylphenyl)-4-(3-chlorophyridin-2-yl)tetrahydropyrazine-1(2H)-carbox-amide (BCTC), a Novel, Orally Effective Vanilloid Receptor 1 Antagonist with Analgesic Properties: II. In Vivo Characterization in Rat Models of Inflammatory and Neuropathic Pain," J. Pharmacol. Exper. Therapeutics 306(1):387-393 (2003)
	C41	

EXAMINER	Af My Mu	DATE CONSIDERED $4/3/2006$
*EYAMINER: I	nitial if reference considered, whether or not citation	n is in conformance with MPEP 609: Draw line through citation if not in conformance and not



Substitute for Form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)

ATTY DOCKET NO.	APPLICAT	TON NO.		
6750-174-999				
(CAM No. 305158-999172) 10/625,708				
APPLICANT:				
Donald J. KYLE et al.				
FILING DATE:	ART UNIT:	CONF. NO.:		
July 24, 2003	1624	8122		

	U.S. PATENT DOCUMENTS					
EXAMINER'S INITIALS*	Cite No.	DOCUMENT NUMBER	DATE MM/DD/YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	A28		·			

	FOREIGN PATENT DOCUMENTS						
EXAMINER'S INITIALS*	Cite No.	Country Code, Number, Kind of Code (if known)	DATE MM/DD/YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	TRANSLA	ATION
						YES	NO
KN	B16	WO 00/42852	07/27/2000	Smithkline Beecham Corp.			
1.	B17						

		NON PATENT LITERATURE DOCUMENTS
EXAMINER'S INITIALS*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, etc.,), date, page(s)s, volume, publisher, city and/or country where published., etc.
	C41	

4/3/2006 **EXAMINER** DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.